Camilla Sandberg
Chief Executive Officer en MIRIS HOLDING AB .
Perfil
Camilla Myhre Sandberg is currently the Chief Executive Officer at Miris Holding AB since 2016.
She is also an Independent Director at Monivent AB and NextCell Pharma AB.
Previously, she worked as the Vice President-Sales & Marketing at BioLamina AB.
Ms. Sandberg completed her undergraduate degree in 1996 and MBA in 1998 from the University of Oslo.
Cargos activos de Camilla Sandberg
| Empresas | Cargo | Inicio |
|---|---|---|
| MIRIS HOLDING AB | Chief Executive Officer | 04/10/2016 |
| NEXTCELL PHARMA AB | Director/Board Member | 01/01/2017 |
| MONIVENT AB | Director/Board Member | - |
Antiguos cargos conocidos de Camilla Sandberg.
| Empresas | Cargo | Fin |
|---|---|---|
BioLamina AB
 BioLamina AB BiotechnologyHealth Technology BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden. | Sales & Marketing | - |
Formación de Camilla Sandberg.
| University of Oslo | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| MIRIS HOLDING AB | Electronic Technology |
| MONIVENT AB | Health Technology |
| NEXTCELL PHARMA AB | Health Technology |
| Empresas privadas | 1 |
|---|---|
BioLamina AB
BioLamina AB BiotechnologyHealth Technology BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden. | Health Technology |
- Bolsa de valores
- Insiders
- Camilla Sandberg
